Quantum BioPharma Executives Consolidate Voting Control Through $750 Private Placement
TL;DR
Quantum BioPharma's private placement gives controlling shareholders 75% voting power, securing strategic control for advancing neurodegenerative and metabolic disorder treatments.
Quantum BioPharma will issue 30 Class A shares at $25 each in a non-brokered private placement, raising $750 for general working capital purposes.
This funding supports Quantum BioPharma's development of treatments for multiple sclerosis and alcohol misuse disorders, potentially improving patient outcomes worldwide.
Quantum BioPharma retains 20% ownership in Unbuzzd Wellness and receives royalties up to $250 million from their consumer health product sales.
Found this article helpful?
Share it with your network and spread the knowledge!
Quantum BioPharma Ltd. has announced a non-brokered private placement of up to 30 Class A multiple voting shares at $25 per share, aiming to raise gross proceeds of up to $750. The biopharmaceutical company, which focuses on treatments for neurodegenerative, metabolic, and alcohol misuse disorders, received shareholder approval for this offering on September 26, 2025. The placement is expected to be fully subscribed by entities controlled by company executives Zeeshan Saeed and Anthony Durkacz.
The completion of this private placement will have significant implications for the company's governance structure. Upon closing, the voting rights attached to the Class A shares will increase to 75.27%, effectively restoring them to nearly their original level when Quantum BioPharma went public in 2018. This substantial increase in voting control for the founding executives represents a consolidation of decision-making power within the company's leadership at a critical juncture in its development pipeline.
Proceeds from the offering are designated for general working capital purposes as the company advances its portfolio of innovative assets and biotech solutions. Quantum BioPharma's research and development efforts are primarily conducted through its wholly owned subsidiary, Lucid Psycheceuticals Inc., which is focused on developing the lead compound Lucid-MS. This patented new chemical entity has demonstrated potential in preclinical models to prevent and reverse myelin degradation, the underlying mechanism of multiple sclerosis.
The company maintains a diverse portfolio that includes its unbuzzd(TM) technology, which was spun out to Unbuzzd Wellness Inc. Quantum BioPharma retains 20.11% ownership in Unbuzzd Wellness Inc. as of March 31, 2025, along with royalty payments of 7% of sales until payments total $250 million, after which the royalty drops to 3% in perpetuity. The company also maintains full rights to develop similar products for pharmaceutical and medical applications. Additional strategic investments are managed through FSD Strategic Investments Inc., another wholly owned subsidiary that represents loans secured by residential or commercial property. Investors can access the latest news and updates relating to QNTM in the company's newsroom at https://ibn.fm/QNTM.
Curated from InvestorBrandNetwork (IBN)
